bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

bioAffinity Technologies (Nasdaq: BIAF) announced the discovery of a potential broad-spectrum cancer therapy utilizing small interfering RNAs (siRNAs) to selectively kill cancer cells by targeting specific cell surface receptors, CD320 and LRP2. Data presented at the 2025 RNA Therapeutics Conference demonstrates this approach effectively kills cancer cells across multiple tumor types, including lung, breast, and prostate, while sparing normal cells, and is the subject of a recently issued U.S. patent and a China patent grant notification. This novel therapeutic strategy positions bioAffinity favorably within the rapidly expanding RNA-based cancer therapeutics market, offering significant commercial potential for targeted treatments.

Analysis

bioAffinity Technologies (BIAF) has disclosed a significant development in its therapeutic pipeline, presenting data on a novel siRNA-based cancer therapy. The approach, which targets the dual suppression of cell surface receptors CD320 and LRP2, has demonstrated broad-spectrum efficacy in pre-clinical models, selectively killing cancer cells across major types including lung, breast, and prostate while leaving normal cells unharmed. The strategic value of this discovery is substantially enhanced by the recent issuance of a U.S. patent and a notification of patent grant from China, creating a strong intellectual property foundation. This positions BIAF to capitalize on the rapidly growing RNA-based therapeutics market. While the company already has a commercialized diagnostic product, CyPath® Lung, this therapeutic breakthrough represents a pivotal expansion of its oncology focus, though it remains in the development stage with inherent risks as noted in its forward-looking statements.

Key Decisions for Investors

• The newly secured U.S. and Chinese patents for a broad-spectrum cancer therapy represent a significant de-risking event and a potential long-term value driver, warranting a reassessment of the company's intellectual property portfolio.
• Investors should monitor for forthcoming data and milestones related to the clinical translation of this siRNA therapy, as its current validation is based on pre-clinical findings and subject to drug development risks.
• Consider the company's dual-platform structure, with revenue-generating potential from its CyPath® Lung diagnostic test providing a potential buffer while the high-growth, early-stage therapeutic pipeline matures.
• Given the high market impact score and strongly positive sentiment, short-term volatility is likely, and investors should assess entry points based on their risk tolerance for early-stage biotechnology assets.